U.K. Approves Vertex Pharmaceutical and CRISPR's 'Genetic Scissors' Treatment

A Nobel Prize-winning gene editing therapy has been conditionally approved in the U.K., as U.S. regulators near decision.

Related Keywords

William Blair ,Josh Nathan Kazis ,Tim Lugo ,Andrew Obenshain ,William Blair Lugo ,Samarth Kulkarni ,Drug Administration ,Vertex Pharmaceuticals ,Nobel Prize ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Trusts Funds Financial Vehicles ,Private Equity ,Scientific Research Services ,Healthcare Life Sciences ,Alternative Investments ,Business Consumer Services ,Biopharmaceuticals ,Financial Services ,Investing Securities ,Medical Research Services ,Drug Discovery Development ,Healthcare Support Services ,Diagnostic Medical Research Services ,Venture Capital ,Regulation Government Policy ,Corporate Industrial News ,Political General News ,Gene Cell Therapy ,Health ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Biotech And Pharma ,Companies ,Economy Amp Policy ,Regulation ,Bluebird Bio ,Blue ,Crispr Therapeutics ,Crsp ,Vrtx ,S Amp Ampp 500 Index ,Spx ,Government Policy ,Corporate ,Industrial News ,Political ,General News ,Gene ,Cell Therapy ,Medical Treatments ,Procedures ,Trusts ,Funds ,Financial Vehicles ,Healthcare ,Life Sciences ,Business ,Consumer Services ,Investing ,Securities ,Drug Discovery ,Development ,Diagnostic ,